| abstract |
The present invention provides an inhibitor of the complement pathway for treating ocular diseases. The present invention relates to age-related macular degeneration (AMD), diabetic retinopathy, ocular angiogenesis (such as ocular neovascularization that affects choroidal, corneal, or retinal tissue), and complement activation. A complement inhibitor for treating an eye-related condition or disease such as other ocular condition involved in Treatment of AMD includes both dry and wet forms of AMD. The complement inhibitors of the present invention include the alternative complement pathway such as factor D, properdin, factor B, factor Ba and factor Bb, and C3a, C5, C5a, C5b, C6, C7, C8, C9, and Inhibitors that inhibit the classical complement pathway such as C5b-9 include, but are not limited to. 【Selection chart】 None |